Milgamma Mono 150 Dragenopharm Treatment Treatment of Multiple Neuritis (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Benfotiamine

Ingredient

Composition information	Content
Benfotiamine	150mg

Uses

Indications

Milgamma Mono 150 drugs are indicated in the following cases:

Treatment of diabetes with diabetes with symptoms and multiple neuritis due to alcoholism. Patients with diabetes often suffer from plasma lacking in plasma, about 75% compared to healthy people.

Benfotiamin is a substance belonging to the oil -shaped thiamin group, thiamin conductors (such as acetiamin, benfotiamin or furriamin) converted into thiamin diphosphate (TDP) with biological activity in the body.

Mechanism of action:

Thiamin Diphosphate acts as a pyruvate conversion into acetyl-coa, and is the same element of transketolase in the pentose phosphate cycle. Besides, this substance also plays the role of converting alpha-ketoglutarate into success-coa in the Citric Acid Cycle. Among other functions, cocarboxylase is a coenzyme that plays a hydrogen reduction role of Pyruvate, playing a key role in the burning of the road. Because the energy used in nerve cells is mainly due to the burning of sugar, the supply of sufficient amount of thiamin is essential for nerve activity. When glucose concentration increases, there is an increase in the demand for thiamin.

High plasma glucose levels lead to high glucose concentration in intracellular and nerve cells that cause biochemical disorders. The four main molecular mechanisms associated with glucose damage: increasing the polyol metabolism path, increasing the hexosamine metabolism path, increasing the formation of the final products of the Glycate process (Advance Glycation Endproduct: AGE), and the ISOFOFF PKC activity through the synthesis of lipids Diacylglycerol information (DAG). DAG). DAG). DAG). DAG). In the aortic endothelial cells, high blood sugar also triggers the copy of the money causing the inflammation of NF -кB.

Three of the main biochemical paths of the disease is the Hexosamine path, the path of Age and the diacylglycerol (DAG) -Protein Kinase C (PKC), which is activated by the increase in glycolytic metabolites, Glyceraldehydes-3-Phosphate and Fructose-6-GHOSPHATE Glyceraldehydes phosphate dehydrogenase (Gapdh).

In the pentose phosphate cycle, the Transketolase enzyme can transfer excess fructose-6-phosphate and glyceraldehyd-3-phosphate into pentose-5-phosphate and erythrose-4-phosphate. Transketolase is a measure to determine the velocity of non -oxidant reactions in the pentose phosphate cycle. The status and direction of the reaction due to transketolase depends on the concentration of the substrate.

Completely activated transketolase can lead to increased glyceraldehyd-3-phosphate and fructose-6-phosphate into pentose-5-phosphate and erythrose-4-phosphate. However, on Vivo, due to the concentration of transketolase metabolites at least 1 step lower in the amplitude of KM value, the condition and direction of the reaction due to Transketolase are determined by the substrate concentration. Therefore, the increase in fructose-6-phosphate and glyceraldehyd-3-phosphate caused by high blood sugar can turn these metabolites into pentose-6-phosphate and erythrose-4-phosphate when Transketolase is completely activated by the thiamin element.

benfotiamin inhibits the accumulation of these toxic substances.

Moreover, Benfotiamin promotes recovery after ischemia by the recovery of vascular formation and inhibit blood vessel apoptosis. These results show that treatment with benfotiamin to prevent damage to organs caused by hyperglycemia in a complex path, because the activation of Transketolase seems to play a particularly important role.

pharmacokinetic

benfotiamin is a precursor of vitamin B1.

After drinking, under the effect of phosphatase enzymes, the reduction of benfotiamin phosphorylation into the form of S-benzoylthiamine (SBT) of the intestinal body. SBT absorbs more than the water -body thiamin conductor because the oil molecules absorb by passive diffusion, while absorbing Thiamin affects the dual transport mechanism dependent on the dose: positive transportation depends on Na+ and energy at less than 2μmol, and passive diffusion at a larger concentration. Therefore, the concentration of thiamin in the blood and tissue will be high when using benfotiamin compared to the body of water, even when taking benfotiamine at a lower dosage.

The benzoyl group separates with the closing of Thiamin, performed in the intestinal mucosa and on cell fences containing thioesterase. In the process of passing through the mucosa, compounds containing sulfhydryl groups such as cystein and glutathion can quickly strike the thiamin thiamin derivatives in the intracellular.

Inside the cell, Thiamin Kinase converts Thiamin into Coenzyme with activity, Thiamin Diphosphate (TDP), Thiamine Monophosphate (TMP) and Thiamine Triphosphate (TTP). Obviously, the concentration of thiamin and active coenzymes in the cells when using benfotiamin is higher than the oral thiamin thiamin derivatives. Thiamin is stored with high concentrations in tissue and coenzyme quickly excreted through the kidneys and excreted into urine in non -metabolic form, free form or phosphorylation, or metabolic substances such as pyrimidine and thiazol.

Before taking Milgamma Mono 150 Dragenopharm Treatment Treatment of Multiple Neuritis (3 blisters x 10 tablets)

How to use

The drug should be taken with 1 glass of water and away from meals. In case of forgetting to use, patients should continue to use the drug as previous use.

Dosage

Adults

Unless prescribed, the initial dose usually from 300 - 450mg Benfotiamin depends on the severity of the neurological disease for a minimum of 4-8 weeks, taking 1 capsule/time, 2-3 times a day.

Then dose depends on the level of treatment. Unless prescribed, should take 1 capsule/time a day.

Children

Safety and effectiveness of the drug is not established.

Patients with liver failure or kidney failure

This object can use the usual dose.

Time to use the drug depends on the level of treatment.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? There is no special treatment in case of overdose. If signs of overdose should be treated with symptoms.

What to do when forgetting 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Milgamma Mono 150, you may experience unwanted effects (ADR).

The immune system disorder: Very rare with hypersensitivity reactions such as urticaria, rash, anaphylaxis.

Stomach disorders: On Benfotiamin's clinical studies, stomach disorders such as nausea and discomfort in the gastrointestinal tract are recorded in cases where Benfotiamin is only used. However, the frequency is not significantly different between the placebo group and the treatment group. The cause and effect of Benfotiamin and these disorders are unclear and may depend on the dose.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Milgamma Mono 150 drug contraindicated in the following cases:

sensitive to benfotiamin/thiamin or one of the ingredients of the drug

Precautions when using

There is no data that shows the adverse effects on the ability to focus, reflexes, combined with the report. There is no special recommendation for this effect.

The ability to drive and operate machinery

Be careful when used for driving objects and operating machinery.

Pregnancy

Inexperienced use of benfotiamin for pregnant women. Although the harmful effects are not set, nor should they use drugs on this object.

During pregnancy, the daily dosage of vitamin B1 is 1.4 - 1.6mg. Higher doses are only for patients with vitamin B1 deficiency, because so far the safety dose is higher than the recommended dose has not been recorded.

Breastfeeding period

Inexperienced use of Benfotiamin for breastfeeding women. Although the harmful effects are not set, nor should they use drugs on this object.

During breastfeeding, the daily dosage of vitamin B1 is 1.4 - 1.6mg. Higher doses are only for patients with vitamin B1 deficiency, because so far the safety dose is higher than the recommended dose has not been recorded. Vitamin B1 can be distributed into breast milk.

Drug interaction

Thiamin is lost in activity by 5-Fluorouracil due to this inhibitor of the phosphorylation process of Thiamin into Thiamin Pyrophosphate.

Interaction between food-food: Unknown.

Storage

In a dry place, avoid light, temperatures below 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.